Mary Tagliaferri, MD

Mary Tagliaferri, M.D., has been a member of our Board of Directors since February 2024. Dr. Tagliaferri has 28 years of experience in pharmaceutical drug development in oncology, immunology and women’s health that includes extensive regulatory expertise. She is currently the Chief Medical Officer and Senior Vice President of Nektar Therapeutics, where she is responsible for numerous clinical studies evaluating novel therapeutics in oncology and establishing key strategic partnerships. Prior to joining Nektar in 2015, she served as Chief Medical Officer for KangLaiTe-USA, a privately held biotechnology company which develops oncology drug candidates in multiple solid tumor settings. Dr. Tagliaferri was also a Co-Founder, President and Chief Medical Officer of BioNovo, where she led the company’s clinical drug development strategy and global regulatory affairs, data management and biostatistics, and oversaw clinical operations and compliance. Dr. Tagliaferri currently serves on the board of Enzo Biochem, Inc. and she served on the board of RayzeBio, Inc. from 2021 until the company’s acquisition by Bristol-Myers Squibb in 2024. Dr. Tagliaferri earned her B.S. degree from Cornell University and her M.D. from the University of California, San Francisco (UCSF). Dr. Tagliaferri was honored as an Eminent Woman Leader in Healthcare by Inc. Magazine in 2023. She was named to the Women who Lead in Life Sciences and Most Influential Women in Business lists by the San Francisco Business Times in 2019. Dr. Tagliaferri was also recognized as Woman of the Year in 2012 by the State of California, Assembly District 14. She has been lead author or contributor to approximately 90 peer-reviewed journal publications.